Madrigal secures Ribo's GalSTAR siRNA platform to expand MASH treatment pipeline

Madrigal secures siRNA platform to broaden MASH treatment strategy

Strategic licensing widens Madrigal's liver-directed arsenal

Madrigal Pharmaceuticals is gaining exclusive worldwide rights to six preclinical small‑interfering‑RNA (siRNA) programs and to Ribo Life Science’s liver‑targeting GalSTAR™ delivery platform, aiming to expand its therapeutic approach to metabolic dysfunction‑associated steatohepatitis (MASH). The agreement, announced by Suzhou Ribo and its subsidiary Ribocure, grants Madrigal the ability to develop, manufacture and commercialize multiple siRNA assets that target pathways implicated in MASH, a condition linked to cirrhosis, liver failure and liver cancer.

Company executives present the deal as a strategic fit that pairs Madrigal’s clinical experience in MASH with Ribo’s RNA‑interference capabilities. Madrigal, cited by Ribo as the company that brought the first approved MASH therapy to market, is positioned to pursue complementary, multimechanistic regimens using RNA‑based agents to tackle the complex biology of liver disease. The collaboration explicitly targets unmet needs in a disease with rising prevalence and substantial morbidity, including its role as a leading cause of liver transplantation.

Technically, the agreement gives Madrigal access to GalSTAR™ — a validated liver‑targeting siRNA platform — and to Ribo’s proprietary chemical modification technologies meant to enhance siRNA stability, delivery and potency. The pact also includes an option for both parties to expand into additional siRNA programs, including development of bispecific siRNAs designed to simultaneously silence two disease‑driving genes, and allows joint nomination of future targets and shared preclinical data to support regulatory filings across global markets.

Deal economics and operational scope

Financial terms provide Ribo with a $60 million upfront payment and potential cumulative development, regulatory and commercial milestone payments that can reach $4.4 billion, plus royalties on net sales. The structure secures Madrigal’s global commercialization rights while allowing technical collaboration, with both companies retaining the ability to leverage the partnership for emerging‑market access and region‑specific regulatory strategies.

Clinical and market context

Ribo executives underline the collaboration’s aim to move liver‑directed siRNA treatments toward clinical development as MASH becomes a leading cause of liver transplantation among women and a major driver of liver‑related mortality. Both firms emphasize accelerating preclinical programs into differentiated therapeutic candidates that could address the multi‑factorial nature of MASH and its life‑threatening comorbidities.